Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

NRBO NeuroBo Pharmaceuticals

13.260
-0.430-3.14%
Close 10/03 16:00 ET
13.2600.0000.00%
Pre Mkt Price 10/04 04:01 ET
High
13.675
Open
13.340
Turnover
1.69M
Low
12.680
Pre Close
13.690
Volume
128.48K
Market Cap
11.78M
P/E(TTM)
Loss
52wk High
65.997
Shares
888.69K
P/E(Static)
Loss
52wk Low
7.395
Float Cap
5.64M
Bid/Ask %
-33.33%
Historical High
16192.494
Shs Float
425.38K
Volume Ratio
0.52
Historical Low
7.380
Dividend TTM
--
Div Yield TTM
--
P/B
1.33
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
30.20%
Amplitude
7.27%
Avg Price
13.165
Lot Size
1
Float Cap
5.64M
Bid/Ask %
-33.33%
Historical High
16192.494
Shs Float
425.38K
Volume Ratio
0.52
Historical Low
7.380
Dividend TTM
--
P/B
1.33
Dividend LFY
--
Turnover Ratio
30.20%
Amplitude
7.27%
Avg Price
13.165
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Boston, MA.
CEO: Dr. Ben Gil Price
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...